| 75367-3 |
Buprenorphine |
MCnt |
Meconium |
Pt |
Qn |
Confirm |
|
ACTIVE |
Buprenorphine [Mass/mass] in Meconium by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mg |
|
|
|
|
|
|
DRUG/TOX |
|
75367-3 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Buprenorphine Mec Cfm-mCnt |
|
|
|
|
|
Addiction; BU; BUP; Bupe; Buprenex; buprenorphine HCI; Buprex; Butrans; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Finobrin; GCMS; Illicit; LC/MS/MS; Mass content; Mec; Norspan; Point in time; PotentialForAbuse; Prefin; QNT; Quan; Quant; Quantitative; Random; Suboxone; Subutex; Temgesic |
2.5 |
2.5 |
|
|
|
|
|
|
|
ng/mg |
|
|
|
0 |
| 75368-1 |
Buprenorphine |
MCnc |
Ser/Plas/Bld |
Pt |
Qn |
|
|
ACTIVE |
Buprenorphine [Mass/volume] in Serum, Plasma or Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
75368-1 |
|
|
|
|
Both |
|
|
|
0 |
Buprenorphine SerPlBld-mCnc |
|
|
|
|
|
Addiction; Blood; BU; BUP; Bupe; Buprenex; buprenorphine HCI; Buprex; Butrans; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Finobrin; Illicit; Level; Mass concentration; Norspan; Pl; PlasBld; Plasma; Plsm; Point in time; PotentialForAbuse; Prefin; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; SerPlBld; Serum; Serum or plasma; Serum, plasma or whole blood; SR; Suboxone; Subutex; Temgesic; WB; Whole blood |
2.73 |
2.5 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 75369-9 |
Diuretics |
Imp |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Diuretics [Interpretation] in Urine Qualitative by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
75369-9 |
|
Screen |
|
|
Observation |
|
|
|
0 |
Diuretics Ur Scn-Imp |
|
|
|
|
|
diuretic; DRUG/TOXICOLOGY; Drugs; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Ordinal; Point in time; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; UA; UR; Urn |
2.73 |
2.5 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 7537-4 |
Quercus alba basophil bound Ab |
ACnc |
Bld |
Pt |
Qn |
LHR |
|
ACTIVE |
White Oak triggered histamine release [Units/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ALLERGY |
|
7537-4 |
|
LHR |
|
|
Both |
|
|
|
0 |
White Oak BasoBnd Ab Qn |
|
|
|
Y |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Associated; Autoantibodies; Autoantibody; Baso; BasoBnd Ab; Basophil release; Basophils; Basos; Blood; bnd; Bph; Leukocyte histamine reaction; Leukocyte histamine release; Oak; Point in time; QNT; Quan; Quant; Quantitative; Random; t007; t7; WB; WBC release; White oak; Whole blood |
2.69 |
1.0h(2) |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 75370-7 |
Norbuprenorphine |
MCnc |
Ser/Plas/Bld |
Pt |
Qn |
|
|
ACTIVE |
Norbuprenorphine [Mass/volume] in Serum, Plasma or Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
75370-7 |
|
|
|
|
Both |
|
|
|
0 |
Norbuprenorphine SerPlBld-mCnc |
|
|
|
|
|
Addiction; Blood; Buprenorphine metabolite; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Level; Mass concentration; NBU; norBUP; Pl; PlasBld; Plasma; Plsm; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; SerPlBld; Serum; Serum or plasma; Serum, plasma or whole blood; SR; WB; Whole blood |
2.73 |
2.5 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 75371-5 |
Bartlett score |
Score |
Sputum |
Pt |
Ord |
Microscopy.light |
|
ACTIVE |
Bartlett score of Sputum Qualitative by Light microscopy |
|
MIN |
DefinitionDescription |
|
|
score |
|
|
|
|
|
|
SPEC |
|
75371-5 |
|
Microscopy.light |
|
|
Both |
|
|
|
0 |
Bartlett score Spt Ql Micro |
|
|
|
|
|
LM; Lower respiratory; Micro; Micros; Microscopic; Ordinal; Point in time; QL; Qual; Qualitative; Random; Scale; Screen; SPEC; Spt; Sputum |
2.5 |
2.5 |
|
|
|
|
|
|
|
{score} |
|
|
|
0 |
| 75372-3 |
Hexane |
MCnc |
Ser/Plas |
Pt |
Qn |
Screen |
|
ACTIVE |
Hexane [Mass/volume] in Serum or Plasma by Screen method |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
DRUG/TOX |
|
75372-3 |
|
Screen |
|
|
Both |
|
|
|
0 |
Hexane SerPl Scn-mCnc |
|
|
|
|
|
Addiction; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Level; Mass concentration; n-hexane; Pl; Plasma; Plsm; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Scn; Scr; Scrn; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.5 |
2.5 |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
| 75373-1 |
Erythrocytes.fetal/2000 erythrocytes |
NFr |
Bld |
Pt |
Qn |
Kleihauer-Betke |
|
ACTIVE |
Erythrocytes.fetal/2000 erythrocytes in Blood by Kleihauer-Betke method |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
75373-1 |
|
Kleihauer-Betke |
|
|
Both |
|
|
|
0 |
Fetal RBC/2000 RBC NFr Bld Kleih Betke |
|
|
|
|
|
2000 RBC; Acid elution; Blood; Discocytes; Erthrocyte; Erythrocyte; Fetal cells; Fetal maternal hemorrhage screen; Fetal RBC; HEMATOLOGY/CELL COUNTS; Hemoglobin F-loaded erythrocytes; KB; Kleih Betke; Kleihauer stain; Kleihauer test; Kleihauer-Betke stain; Kleihauer-Betke test; Kleihauer-Braun-Betke; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; RBC; RBCS; Red blood cell; Red blood cells; Red blood corpuscle; Red blood corpusles; Red cell; Red cells; WB; Whole blood |
2.73 |
2.5 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 75374-9 |
Other cells/Leukocytes |
NFr |
CSF |
Pt |
Qn |
Manual count |
|
ACTIVE |
Other cells/Leukocytes in Cerebral spinal fluid by Manual count |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
75374-9 |
|
Manual count |
|
|
Observation |
|
|
|
0 |
Other cells NFr CSF Manual |
|
|
|
|
|
Cell; Cellularity; Cerebral spinal fluid; Cerebrospinal Fl; HEMATOLOGY/CELL COUNTS; Leuc; Leuk; Leukocyte; Lkcs; Manl; Number fraction; Othr; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; WBC; WBCs; White blood cell; White blood cells |
2.79 |
2.5 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 75375-6 |
Other cells/Leukocytes |
NFr |
Sputum |
Pt |
Qn |
Manual count |
|
ACTIVE |
Other cells/Leukocytes in Sputum by Manual count |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
75375-6 |
|
Manual count |
|
|
Observation |
|
|
|
0 |
Other cells NFr Spt Manual |
|
|
|
|
|
Cell; Cellularity; HEMATOLOGY/CELL COUNTS; Leuc; Leuk; Leukocyte; Lkcs; Lower respiratory; Manl; Number fraction; Othr; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Spt; Sputum; WBC; WBCs; White blood cell; White blood cells |
2.79 |
2.5 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 75376-4 |
Siderocytes.HPF |
PrThr |
Bld |
Pt |
Ord |
Microscopy.light |
|
ACTIVE |
Siderocytes per HPF [Presence] in Blood by Light microscopy |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
75376-4 |
|
Microscopy.light |
|
|
Both |
|
|
|
0 |
Siderocytes.HPF Bld Ql Smear |
|
|
|
|
|
Blood; HEMATOLOGY/CELL COUNTS; LM; Micro; Micros; Microscopic; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; WB; Whole blood |
2.56 |
2.5 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 75377-2 |
Dengue virus NS1 Ag |
PrThr |
Ser/Plas/Bld |
Pt |
Ord |
IA.rapid |
|
ACTIVE |
Dengue virus NS1 Ag [Presence] in Serum, Plasma or Blood by Rapid immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
75377-2 |
|
IA.rapid |
|
|
Both |
|
|
|
0 |
DENV NS1 Ag SerPlBld Ql IA.rapid |
|
|
|
|
|
Antigen; Antigens; Blood; Breakbone fever; Dengue fever; Denv; DENV NS1; EIA; ELFA; ELISA; Enzyme immunoassay; Flavivirus; IAA; ID; Infectious Disease; InfectiousDisease; MEIA; Microbiology; NS1; Ordinal; Pl; PlasBld; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; SerPlBld; Serum; Serum or plasma; Serum, plasma or whole blood; SR; SUDS; WB; Whole blood |
2.73 |
2.5 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 75378-0 |
Hepatitis B virus core Ab |
PrThr |
Ser/Plas/Bld |
Pt |
Ord |
IA.rapid |
|
ACTIVE |
Hepatitis B virus core Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
75378-0 |
|
IA.rapid |
|
|
Observation |
|
|
|
0 |
HBV core Ab SerPlBld Ql IA.rapid |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; anti-HBc; Autoantibodies; Autoantibody; Blood; EIA; ELFA; ELISA; Enzyme immunoassay; HBc; HBV; HBV core; Hep; Hep B; Hepatis; Hepatit; Hepatitis Bc; Hepatology; HepB; IAA; ID; Infectious Disease; InfectiousDisease; Liver; MEIA; Microbiology; Ordinal; Pl; PlasBld; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; SerPlBld; Serum; Serum or plasma; Serum, plasma or whole blood; SR; SUDS; WB; Whole blood |
2.56 |
2.5 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 75379-8 |
Norbuprenorphine |
MCnt |
Meconium |
Pt |
Qn |
Confirm |
|
ACTIVE |
Norbuprenorphine [Mass/mass] in Meconium by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mg |
|
|
|
|
|
|
DRUG/TOX |
|
75379-8 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Norbuprenorphine Mec Cfm-mCnt |
|
|
|
|
|
Addiction; Buprenorphine metabolite; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Mass content; Mec; NBU; norBUP; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random |
2.5 |
2.5 |
|
|
|
|
|
|
|
ng/mg |
|
|
|
0 |
| 7538-2 |
Avena sativa Ab.IgG |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Oat IgG Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
kIU/L |
|
|
|
|
|
|
ALLERGY |
|
7538-2 |
|
|
|
|
Both |
|
|
|
0 |
Oat IgG Qn |
|
|
|
Y |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; f007; f7; Immune globulin G; Immunoglobulin G; Oat; Oats; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.73 |
1.0h(2) |
|
|
|
|
|
|
|
k[IU]/L |
|
|
|
0 |
| 75380-6 |
SERPING1 gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
SERPING1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
75380-6 |
|
Molgen |
|
|
Both |
|
|
|
0 |
SERPING1 Mut Anl Bld/T |
|
|
|
|
|
Blood; C1 Inhibitor; C1IN; C1INH; C1-INH; C1NH; Complement c1 esterase inhibitor; Document; Finding; Findings; Genetics; HAE1; HAE2; Hereditary angioedema; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; PCR; Point in time; Random; serpin peptidase inhibitor, clade G (C1 inhibitor), member 1; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.66 |
2.5 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 75381-4 |
TTR gene mutation analysis limited to known familial mutations |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
TTR gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
75381-4 |
|
Molgen |
|
|
Both |
|
|
|
0 |
TTR gene Fam Mut Anl Bld/T |
|
|
|
|
|
Blood; CTS; CTS1; Document; Fam Mut Anl; Finding; Findings; Genetics; HEL111; Heredity; Heritable; HsT2651; Inherited; LMTED; LTD; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mutation; Mutations; Muts; PALB; PCR; Point in time; Random; TBPA; Tissue; Tissue, unspecified; transthyretin; Transthyretin (prealbumin, amyloidosis type I) gene; WB; Whole blood; Whole blood or Tissue |
2.66 |
2.5 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 75382-2 |
ATP7B gene mutation analysis limited to known familial mutations |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
ATP7B gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
75382-2 |
|
Molgen |
|
|
Both |
|
|
|
0 |
ATP7B gene Fam Mut Anl Bld/T |
|
|
|
|
|
ATPase gene; ATPase, Cu++ transporting, beta polypeptide; Blood; CU(2+)- transporting beta polypeptide; Document; Fam Mut Anl; Finding; Findings; Genetics; Heredity; Heritable; Inherited; LMTED; LTD; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mutation; Mutations; Muts; PCR; Point in time; PWD; Random; Tissue; Tissue, unspecified; WB; WC1; WD; Whole blood; Whole blood or Tissue; Wilson disease; WND |
2.66 |
2.5 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 75383-0 |
DMD gene deletion+duplication |
Find |
Amnio fld/CVS |
Pt |
Doc |
MLPA |
|
ACTIVE |
DMD gene deletion and duplication mutation analysis in Amniotic fluid or Chorionic villus sample by MLPA |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.DEL |
|
75383-0 |
|
MLPA |
|
|
Both |
|
|
|
0 |
DMD gene Del+Dup Amn/CVS MLPA |
|
|
|
|
|
AF; Amn; Amn fl; Amn/CVS; Amnio; Amniotic flu; Amniotic fluid; Amplification; BMD; Chorionic villi; Chorionic villus sample; CMD3B; Del; Del+Dup; Deletions; Document; Dp; DXS142; DXS164; DXS206; DXS230; DXS239; DXS268; DXS269; DXS270; DXS272; Dystrophin; Finding; Findings; Molecular pathology; MOLPATH; MOLPATH.DELETIONS; MRX85; Muscular dystrophy, Duchenne and Becker types; Point in time; Pseudohypertrophic progressive; Random |
2.66 |
2.5 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 75384-8 |
PMP22 gene deletion+duplication |
Find |
Bld/Tiss |
Pt |
Doc |
MLPA |
|
ACTIVE |
PMP22 gene deletion and duplication mutation analysis in Blood or Tissue by MLPA |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.DEL |
|
75384-8 |
|
MLPA |
|
|
Both |
|
|
|
0 |
PMP22 gene Del+Dup Bld/T MLPA |
|
|
|
|
|
Amplification; Blood; Charcot-Marie Tooth disease; CMT; CMT1A; CMT1E; Dejerine-Sottas syndrome; Del; Del+Dup; Deletions; Document; Dp; DSS; Finding; Findings; GAS3; GAS-3; Growth arrest specific gene 3; Hereditary neuropathy with liability to pressure palsies; HMSNIA; HNPP; Molecular pathology; MOLPATH; MOLPATH.DELETIONS; peripheral myelin protein 22; PMP-22; Point in time; Random; Sp110; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.66 |
2.5 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 75385-5 |
DMD gene deletion+duplication |
Find |
Bld/Tiss |
Pt |
Doc |
MLPA |
|
ACTIVE |
DMD gene deletion and duplication mutation analysis in Blood or Tissue by MLPA |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.DEL |
|
75385-5 |
|
MLPA |
|
|
Both |
|
|
|
0 |
DMD gene Del+Dup Bld/T MLPA |
|
|
|
|
|
Amplification; Blood; BMD; CMD3B; Del; Del+Dup; Deletions; Document; Dp; DXS142; DXS164; DXS206; DXS230; DXS239; DXS268; DXS269; DXS270; DXS272; Dystrophin; Finding; Findings; Molecular pathology; MOLPATH; MOLPATH.DELETIONS; MRX85; Muscular dystrophy, Duchenne and Becker types; Point in time; Pseudohypertrophic progressive; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.66 |
2.5 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 75386-3 |
MEN1 gene mutation analysis limited to known familial mutations |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
MEN1 gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
75386-3 |
|
Molgen |
|
|
Both |
|
|
|
0 |
MEN1 gene Fam Mut Anl Bld/T |
|
|
|
|
|
Blood; Document; Fam Mut Anl; Finding; Findings; Genetics; Heredity; Heritable; Inherited; LMTED; LTD; MEAI; Menin; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; multiple endocrine neoplasia I; Multiple endocrine neoplasia type I; Mut; Mutation; Mutations; Muts; PCR; Point in time; Random; SCG2; Tissue; Tissue, unspecified; WB; Wermer syndrome; Whole blood; Whole blood or Tissue; Zollinger-Ellison syndrome |
2.66 |
2.5 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 75387-1 |
INS gene full mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Sequencing |
|
ACTIVE |
INS gene full mutation analysis in Blood or Tissue by Sequencing |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
75387-1 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
INS Full Mut Anl Bld/T Seq |
|
|
|
|
|
Blood; Document; Finding; Findings; full gene sequencing; Full Mut Anl; Genetics; Heredity; Heritable; high-throughput sequencing; HTS; IDDM; IDDM1; IDDM2; ILPR; Inherited; insulin; insulin-dependent diabetes mellitus 2; IRDN; MODY10; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mutations; Next generation sequencing; NGS; Point in time; Random; sequencing of entire coding region; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.66 |
2.5 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 75388-9 |
CDKN1B gene mutation analysis limited to known familial mutations |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
CDKN1B gene mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
75388-9 |
|
Molgen |
|
|
Both |
|
|
|
0 |
CDKN1B Fam Mut Anl Bld/T |
|
|
|
|
|
Blood; CDKN4; cyclin-dependent kinase inhibitor 1B; cyclin-dependent kinase inhibitor 1B (p27, Kip1); Document; Fam Mut Anl; Finding; Findings; Genetics; Heredity; Heritable; Inherited; kip1; LMTED; LTD; MEN1B; MEN4; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Multiple endocrine neoplasia type IV; Mut; Mutation; Mutations; Muts; P27KIP1; PCR; Point in time; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.66 |
2.5 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 75389-7 |
CDKN1B gene full mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Sequencing |
|
ACTIVE |
CDKN1B gene full mutation analysis in Blood or Tissue by Sequencing |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
75389-7 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
CDKN1B Full Mut Anl Bld/T Seq |
|
|
|
|
|
Blood; CDKN4; cyclin-dependent kinase inhibitor 1B; cyclin-dependent kinase inhibitor 1B (p27, Kip1); Document; Finding; Findings; full gene sequencing; Full Mut Anl; Genetics; Heredity; Heritable; high-throughput sequencing; HTS; Inherited; kip1; MEN1B; MEN4; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Multiple endocrine neoplasia type IV; Mut; Mutations; Next generation sequencing; NGS; P27KIP1; Point in time; Random; sequencing of entire coding region; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.66 |
2.5 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
